Inspira Technologies Expands U.S. Presence with ART100 Deployment in Top New York Hospital
Event summary
- Inspira Technologies deployed its FDA-cleared ART100 system at a top 10-ranked New York academic medical center on February 18, 2026.
- The system is being integrated into clinical workflows for structured evaluation and potential broader adoption.
- This deployment follows previous commercial activity at other leading U.S. healthcare facilities.
- Mike Hershkovitz, Global VP Sales, emphasized the strategic importance of entering another leading institution in New York State.
The big picture
Inspira Technologies' deployment of the ART100 system in a top-ranked New York hospital underscores its strategic push into the Tier-1 U.S. hospital market. This move aligns with broader industry trends toward advanced respiratory support and real-time blood monitoring solutions. The company's focus on converting evaluations into commercial success will be critical in determining its long-term position in the life-support and MedTech landscape.
What we're watching
- Commercial Pipeline
- How Inspira Technologies will convert high-profile evaluations into a sustainable commercial pipeline.
- Market Expansion
- The pace at which Inspira Technologies can expand its footprint across key U.S. markets.
- Clinical Adoption
- Whether the ART100 system will meet the operational and clinical demands of top-tier U.S. healthcare providers.
Related topics